The 340B Drug Pricing Program is a lifeline for Community Health Centers (CHCs), enabling them to provide affordable, often free, lifesaving medications to low-income patients with chronic illness. For decades, upfront 340B discounts have been a foundation of CHC financial stability, allowing health centers to stretch scarce federal resources and reinvest savings into primary care. CHCs serve 1 in 7 Americans — including over 20 million people living in poverty and 1 in 3 rural residents — who rely on 340B savings for medications treating diabetes, heart disease, asthma, and other chronic conditions. 

That lifeline continues to be under threat. On January 1, 2027, HRSA is set to implement a rebate pilot that replaces upfront discounts with full-price purchases and delayed rebates. This shift will strain CHC budgets, disrupt patient access to essential medications, and divert resources away from care.  

Call to Action: Congress and federal regulators need to hear directly from the communities that rely on 340B. Join us in urging policymakers to delay the rebate pilot, reject unlawful manufacturer restrictions, and preserve 340B as Congress intended. Our patients, health centers, and communities cannot afford to lose this vital resource.